
Product imagery is intended solely for illustrative purposes. Actual medication packaging and pharmacy labeling may differ.
Weight Management
Tirzepatide
A dual-pathway weight-management program for people reviewed and approved by a licensed clinician.
$499
1-month supply · All-inclusive program price
- Online licensed-provider review
- Secure medical intake after checkout
- Ongoing program support by secure message
- Standard shipping
- Routine follow-up required by the program
May be compounded — not FDA-approved
Available in eligible states, subject to pharmacy and regulatory review.
VitaWellRx® notice. VitaWellRx® is a telehealth platform that connects eligible patients with independent US-licensed providers and licensed pharmacy partners. VitaWellRx® is not a pharmacy and does not itself practice medicine. Prescription products are provided only if clinically appropriate after review by a US-licensed provider.
About this program
The VitaWellRx® Tirzepatide program is a clinician-guided weight-management program. Purchase comes first, the secure medical intake follows, and a licensed clinician determines whether treatment is appropriate.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Where a compounded formulation would be used, that is disclosed before fulfilment.
This program is generally considered for adults with weight-related health goals who can be managed safely at a distance.
How it may work
Tirzepatide acts on two incretin pathways rather than one. In general educational terms, those pathways are involved in appetite regulation, insulin response, and gastric emptying.
Whether a dual-pathway product suits you better than a single-pathway one is a clinical judgment, not a purchase decision. This page contains no dosing schedule.
Product status
- Any program here may involve a compounded formulation, which is not FDA-approved.
- Availability depends on independent legal, clinical, and pharmacy review.
Eligibility and provider review
Disclose personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis, gallbladder disease, severe gastrointestinal conditions, diabetes medicines, pregnancy or breastfeeding plans, allergies, and all current medications.
Prescription required. Licensed-provider review required. Not everyone qualifies.
Safety summary
- Gastrointestinal effects are the most commonly described: nausea, vomiting, diarrhoea, constipation, reduced appetite, and abdominal pain.
- Serious risks described for this class include pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycaemia in combination with certain diabetes medicines.
- Seek immediate care for severe or persistent abdominal pain, ongoing vomiting, or allergic symptoms.
